Abbott Enhances Expertise in Information Management with STARLIMS Acquisition
|
By LabMedica International staff writers Posted on 21 Dec 2009 |
Abbott (Abbott Park, IL, USA) has signed an agreement to acquire STARLIMS Technologies Ltd. (Tel Aviv, Israel), a provider of laboratory information-management systems, for approximately U.S. $123 million in cash. The acquisition strengthens Abbott's competitive position in the global diagnostics market, providing advanced web-based applications to help laboratories efficiently store, retrieve, and analyze clinical, managerial, and administrative data.
STARLIMS' web-based technologies will help Abbott customers to operate efficiently across the core laboratory, molecular, and point-of-care segments of the global diagnostics market. As the company is integrated into Abbott's existing portfolio of laboratory information-management products, STARLIMS will continue to support and expand the nonclinical market segments it currently serves.
"We believe our laboratory information management solutions, which are widely used by government, manufacturing and life sciences organizations, have important applications in clinical laboratories for improving the access, exchange and analysis of patient and technical data," said Itschak Friedman, CEO of STARLIMS, who will continue to lead the STARLIMS team after the acquisition closes.
Advanced informatics systems are becoming increasingly important to clinical laboratories as a means to automate the retrieval, communication, and management of medical and laboratory data and aid compliance with global regulatory and industry standards. Informatics systems help laboratories to improve their operating efficiency through process standardization, reduced labor costs, and increased capacity. Improved laboratory operations benefit physicians and patients through improved turnaround times and more consistent interpretation of test results.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture, and marketing of pharmaceutics and medical products, including diagnostics, devices, and nutritionals.
STARLIMS software is used for quality assurance and control, testing and monitoring, and research and development in government, manufacturing, and life sciences organizations. The company's flagship product, STARLIMS improves the reliability of laboratory sampling processes, supports compliance with domestic and international regulations and industry standards, and provides comprehensive reporting, monitoring and analysis capabilities.
Related Links:
Abbott
STARLIMS Technologies Ltd.
STARLIMS' web-based technologies will help Abbott customers to operate efficiently across the core laboratory, molecular, and point-of-care segments of the global diagnostics market. As the company is integrated into Abbott's existing portfolio of laboratory information-management products, STARLIMS will continue to support and expand the nonclinical market segments it currently serves.
"We believe our laboratory information management solutions, which are widely used by government, manufacturing and life sciences organizations, have important applications in clinical laboratories for improving the access, exchange and analysis of patient and technical data," said Itschak Friedman, CEO of STARLIMS, who will continue to lead the STARLIMS team after the acquisition closes.
Advanced informatics systems are becoming increasingly important to clinical laboratories as a means to automate the retrieval, communication, and management of medical and laboratory data and aid compliance with global regulatory and industry standards. Informatics systems help laboratories to improve their operating efficiency through process standardization, reduced labor costs, and increased capacity. Improved laboratory operations benefit physicians and patients through improved turnaround times and more consistent interpretation of test results.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture, and marketing of pharmaceutics and medical products, including diagnostics, devices, and nutritionals.
STARLIMS software is used for quality assurance and control, testing and monitoring, and research and development in government, manufacturing, and life sciences organizations. The company's flagship product, STARLIMS improves the reliability of laboratory sampling processes, supports compliance with domestic and international regulations and industry standards, and provides comprehensive reporting, monitoring and analysis capabilities.
Related Links:
Abbott
STARLIMS Technologies Ltd.
Latest Industry News
- Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
- Diazyme Laboratories Acquires Carolina Liquid Chemistries
- Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean
- Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand
- GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026
- Global Framework Integrates Digital Pathology for Companion Diagnostic Development
- Werfen and Oxford Nanopore Collaborate on Transplant Assay Development
- New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays
- ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026
- Artera to Highlight AI-Based Cancer Risk Stratification at ASCO 2026
- Natera to Present Data on MRD-Guided Cancer Care at ASCO 2026
- Fujifilm Integrates Structured Reporting into Digital Pathology Workflow
- Strategic Collaboration Advances RNA Foundation Models for Precision Oncology
- Partnership Brings Single-Cell Analysis into Clinical Oncology Workflows
- Partnership Aims to Bring Risk-Guided CKD Care to Health Systems
- AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more








